Pittenger & Anderson Inc’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Pittenger & Anderson Inc’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,500	Closed	-$25K	–	393
2018 Q2	$25K	Hold	1,500	–	–	﹤0.01%	293
2018 Q1	$21K	Hold	1,500	–	–	﹤0.01%	301
2017 Q4	$22K	Hold	1,500	–	–	﹤0.01%	315
2017 Q3	$19K	Hold	1,500	–	–	﹤0.01%	312
2017 Q2	$18K	Buy	+1,500	New	+$18.7K	﹤0.01%	315

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Pittenger & Anderson Inc's HZNP Position: Q3 2018 in Review

Pittenger & Anderson Inc sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2018, closing a stake of 1,500 shares — an estimated $25K sold.

Pittenger & Anderson Inc first reported a position in HZNP in Q2 2017 and held it in 5 quarters. The position peaked at $25K in Q2 2018. 221 funds tracked by Wall St. Rank hold HZNP as of Q3 2018.

Pittenger & Anderson Inc reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2018 after selling out during the quarter.
Pittenger & Anderson Inc sold 1,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2018, an estimated $25K.
Pittenger & Anderson Inc first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017 and held it in 5 quarters.
Pittenger & Anderson Inc's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $25K in Q2 2018.
221 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2018.

Based on Pittenger & Anderson Inc's 13F filing for Q3 2018, filed 12 Oct 2018.